PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316286
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1316286
The global inhalation therapy nebulizer market reached US$ 0.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.6 billion by 2030. The global inhalation therapy nebulizer market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030).
There is a growing trend of using nebulizers in homecare settings, increasing the geriatric population, and growing awareness and adoption in emerging markets are some of the trends for the inhalation therapy nebulizer market.
The inhalation therapy nebulizer is a medical device used for delivering medication directly to the lungs through inhalation. It is designed to convert liquid medication into a fine mist or aerosol that can be easily inhaled by the patient. This method of drug delivery is particularly effective for treating respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
The nebulizer consists of several key components. The primary component is the nebulizer chamber, which holds the liquid medication. The chamber is connected to an air compressor or ultrasonic transducer, depending on the type of nebulizer. The compressor or transducer generates a high-velocity flow of air or ultrasonic vibrations, respectively, which agitate the liquid medication, breaking it down into tiny droplets or particles.
Furthermore, the increasing prevalence of respiratory diseases, and advances in nebulizer technology have improved their efficiency, ease of use, and portability, and governments and healthcare organizations in many countries are focusing on improving respiratory care and investing in healthcare infrastructure are the factors expected to drive the market over the forecast period.
On April 2023, QMS MAS, a well-known healthcare and wellness firm, made its direct-to-consumer debut by offering an extensive line of point-of-care devices known as Q Devices. In conjunction with Varanium Cloud Ltd., a renowned digital technology business in India, the company also launched an innovative medical wearable named Vyana. Vyana is intended to fill a void in the medical wearable market by continually monitoring vital signs and giving fast messages to the user and their emergency contacts in the event of severe variations. The gadget is intended for high-risk populations and is likely to be extensively utilized.
These lifestyle monitoring gadgets exceed the highest quality requirements and are in line with the company's objective of encouraging a healthy lifestyle among consumers. The devices are accessible both in shops and online through platforms such as Amazon and the company's website, QDevices.life. Thus, owing to the above factors, the market is expected to drive over the forecast period.
Evaluation of Different Oscillating Positive Expiratory Pressure (OPEP) Devices in Delivering Nebulized Medications is Expected to Drive Global Inhalation Therapy Nebulizer Market Growth
According to Trudell Medical UK Limited Article, published on August 15, 2022, the research looked at how well different OPEP devices delivered nebulized medicine for the treatment of bronchiectasis and COPD. When compared to previous combinations, the AEROBIKA OPEP device and AEROECLIPSE II BAN Nebulizer produced much better outcomes, delivering more than three times the quantity of medicine.
The findings highlight the significance of selecting the right OPEP device and nebulizer combination to optimize medication delivery. Combining OPEP and nebulizer treatment has advantages in terms of patient efficiency, convenience, and adherence, but care must be taken to ensure proper medication delivery. Thus, owing to the above factors, the market is expected to drive over the forecast period.
Compliance and adherence are critical to the efficacy of inhalation treatment. However, patients may have difficulty following their recommended inhalation regimens for a variety of reasons, including forgetfulness, discomfort, and a lack of understanding of the need for adherence.
Forgetfulness is a typical problem for many patients. With hectic schedules and various duties, it's easy to neglect or skip inhalation sessions. Failure to take the prescribed medicine as directed can result in insufficient treatment, lowering the effectiveness of the therapy and perhaps leading to inadequate symptom management.
Inconvenience is another factor that can hinder compliance. Some inhalation devices may be perceived as cumbersome or time-consuming, requiring specific preparation steps or a secluded environment for administration. Patients who find the process inconvenient or disruptive to their daily routines may be more inclined to skip or delay their inhalation sessions, compromising the therapeutic outcomes. Thus, owing to the above factors, the market is expected to hamper over the forecast period.
The impact of COVID-19 on the inhalation therapy nebulizer market has been significant. The respiratory complications associated with COVID-19 created a surge in demand for inhalation therapy nebulizers. These devices are commonly used to deliver medication directly to the lungs, making them crucial for managing respiratory symptoms in COVID-19 patients. The heightened demand for nebulizers resulted in increased market growth.
Due to social distancing measures and the need to minimize in-person healthcare visits, telemedicine, and remote patient monitoring gained prominence during the pandemic. This shift impacted the utilization of nebulizer devices, as some patients opted for alternative treatment options that could be managed remotely. Consequently, this change in patient behavior had a slight negative impact on the growth of the nebulizer market.
Infection prevention and control measures became crucial during the pandemic, leading to a greater emphasis on device cleaning and disinfection protocols. This focus on hygiene and the need for disposable or easily cleanable nebulizer components influenced the market, with a preference for devices that could mitigate infection risks.
Therefore, while the demand for inhalation therapy nebulizers increased due to COVID-19, supply chain disruptions and changes in healthcare delivery methods posed challenges to the market's growth. However, the long-term impact on the market is expected to be positive as the importance of respiratory care remains significant in both COVID-19 and non-COVID-19 scenarios.
The Russian-Ukraine war has had several impacts on various sectors, including the medical industry. The conflict may lead to disruptions in the supply chains of medical devices, including nebulizers. Ukraine is known for its manufacturing capabilities, and if the conflict affects production facilities or transportation routes, it could result in a shortage of nebulizers in the market.
During times of conflict and unrest, there is often an increase in respiratory illnesses due to various factors such as displacement, stress, poor living conditions, and exposure to environmental pollutants. This increased demand for respiratory treatments may lead to a surge in the need for nebulizers as an inhalation therapy option.
The war may place a strain on the healthcare infrastructure in affected areas, leading to a shortage of medical supplies, including nebulizers. The focus of resources might shift towards addressing immediate emergency needs, potentially impacting the availability and distribution of nebulizers.
International sanctions and trade restrictions imposed during the conflict could impact the import and export of medical devices. This could affect the availability of nebulizers in both Ukraine and Russia, as well as other countries involved in the conflict.
COPD from the Application Segment Account for 28.2% of the Market Share Owing to the Increasing Prevalence of COPD, Patient Convenience and Ease of Use, and Advancements in Nebulizer Technology
According to Global Initiative for Chronic Obstructive Lung Disease Report 2022, an estimated 200 million people have COPD, of which about 3.2 million die each year, making it the third-leading cause of death worldwide.
Cigarette smoking is a major environmental risk factor for COPD, leading to respiratory symptoms, lung function abnormalities, and increased mortality rates. However, it's worth noting that not all heavy smokers develop COPD. Passive exposure to different types of tobacco smoke and marijuana also poses a risk. Smoking during pregnancy can affect lung development in the fetus and potentially lead to abnormal immune responses in the future.
In low- and middle-income countries (LMICs), nonsmokers account for a significant portion of COPD cases, potentially up to 60-70%. Household air pollution caused by burning biomass fuels like wood, animal dung, crop residues, and coal in poorly functioning stoves is a common risk factor in LMICs. This household air pollution contributes to over 50% of the global burden of COPD.
COPD in nonsmokers, compared to smokers, is more prevalent among females, and younger individuals, and exhibits similar or milder respiratory symptoms and quality of life impairment. They show different patterns of lung function decline, with more small airway obstruction but less emphysema.
Occupational exposures, such as exposure to organic and inorganic dusts, chemicals, and fumes, are an under-recognized risk factor for COPD. Workplace exposures contribute to a significant fraction of COPD cases, particularly among never-smokers.
Air pollution, including particulate matter, ozone, nitrogen or sulfur oxides, heavy metals, and other pollutants, is a major global cause of COPD. It accounts for approximately 50% of the attributable risk for COPD in LMICs. Chronic exposure to air pollution impairs lung growth in children, accelerates lung function decline in adults, and increases the risk of COPD, especially when combined with other risk factors.
Air pollution also exacerbates COPD symptoms, leading to more frequent exacerbations, hospitalizations, and increased mortality rates. Therefore, there is an increase in demand for inhalation therapy nebulizers. Thus, owing to the above factors, the market segment accounted to hold the largest market share over the forecast period.
North America Accounted for Approximately 38.4% of the Market Share Owing to the Increasing Prevalence of Asthma Cases, Rising Geriatric Population, Well Healthcare Expenditure, and Product launches by the Key Players
The increasing prevalence of asthma cases, technological advancement in nebulizer devices, well-established infrastructure, rising geriatric population, product launches, approval, and acquisitions by the market players are some factors due to which the market is expected to boost in the forecast period.
For instance, according to the Asthma and Allergy Foundation of America Report 2022, approximately 26 million individuals in the United States have asthma, which is equivalent to about 1 out of every 13 people. Out of this total, around 21 million are adults aged 18 and older. Asthma rates are highest among Black adults in the country.
Moreover, asthma is more prevalent in female adults compared to male adults, with approximately 9.7% of women and 6.2% of men being affected. Among children, asthma is a prominent chronic disease, affecting approximately 4.8 million children under the age of 18. Non-Hispanic Black children are over twice as likely to have asthma as non-Hispanic white children. Additionally, asthma is more common among male children than female children, with approximately 7.3% of boys and 5.6% of girls being affected.
Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.
The major global players in the market include: Rossmax International Ltd, Boehringer Ingelheim GmbH, OMRON Corporation, Koninklijke Philips N.V., PARI Pharma, BD, Medline Industries, Inc., Briggs Healthcare, GF Health Products, Inc., and Vectura Group plc among others.
The global inhalation therapy nebulizer market report would provide approximately 61 tables, 59 figures, and 195 Pages.
LIST NOT EXHAUSTIVE